Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-08-01
2006-08-01
Rao, Deepak (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S332000, C514S336000, C546S193000, C546S194000, C546S256000, C546S281400
Reexamination Certificate
active
07084159
ABSTRACT:
The present invention provides compounds of formula I:or a pharmaceutically acceptable derivative o thereof, wherein A, B, Ra, R1, R2, R3, and R4are as described in the specification. These compounds are inhibitors of protein kinase, particularly inhibitors of JNK, a mammalian protein kinase involved cell proliferation, cell death and response to extracellular stimuli; Lck and Src kinase. The invention also relates to methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing those compositions in the treatment and prevention of various disorders.
REFERENCES:
patent: 4940712 (1990-07-01), Walker et al.
patent: 5932576 (1999-08-01), Anantanarayan et al.
patent: 6051574 (2000-04-01), Anthony
patent: 6114333 (2000-09-01), Davis et al.
patent: WO 95/19358 (1995-07-01), None
patent: WO 97/03967 (1997-02-01), None
patent: WO 97/09325 (1997-03-01), None
patent: WO 98/28282 (1998-07-01), None
patent: WO 99/18099 (1999-04-01), None
patent: WO 01/12621 (2001-02-01), None
patent: WO 01/29009 (2001-04-01), None
Douglas, Jr. Introduction to Viral Diseases, Cecil Textbook of Medicine, 20thEdition, vol. 2, pp. 1739-1747, 1996.
Layzer, Degenerative Diseases of the Nervous System, Cecil Textbook of Medicine, 20thEdition, vol. 2, pp. 2050-2057, 1996.
Damasio, Alzheimer's Disease and Related Dementias, Cecil Textbook of Medicine, 20thEdition, vol. 2, pp. 1992-1996, 1996.
Simone, Oncology: Introduction, Cecil Textbook of Medicine, 20thEdition, vol. 1, pp. 1004-1010, 1996.
Casanova et al., PubMed Abstract (Rev Neurol. 28(9):909-15), May 1999.
Holzheimer, PubMed Abstract (J Chemother. 13 Spec No. 1(1):159-72), Nov. 2001.
van Deventer, PubMed Abstract (Intensive Care Med.26 Suppl. 1:S98-102), 2000.
Green et al., PubMed Abstract (Immunol Rev. 169:11-22), Jun. 1999.
Rasmussen, PubMed Abstract (Dan Med Bull. 47(2):94-114), Apr. 2000.
Bremner et al., Therapy of Crohn's Disease in Childhood, Expert Opinion Pharmacother. 3(7):809-825, 2002.
Robinson, Medican Therapy of Inflammatory Bowel Disease for the 21stCentury, European Journal of Surgery Suppl 582:90-98, 1998.
Singh et al., Immune Therapy in Inflammatory bowel disease and models of colitis, British Journal of Surgery, 88, 1558-1569, 2001.
Wachlin et al., IL-1beta, IFN-gamma and TNF-alpha increase vulnerability of pancreatic beta cells to autoimmune destruction, Journal of Autoimmunity, 20, pp. 303-312, 2003.
Beers et al., Crohn's Disease; Ulcerative Colitis; Adult Respiratory Distress Syndrome, The Merck Manual of Diagnosis and Therapy, Seventeenth Edition (online), 1999.
Elgert, Autoimmunity, Immunology—Understanding the Immune System, pp. 315-330, 1996.
Traxler, Oncologic, Endocrine & Metabolic Protein Tyrosine Kinase Inhibitors in cancer treatment, Exp. Opin. Ther. Patents, 7(6):571-588, 1997.
Cao Jingrong
Gao Huai
Green Jeremy
Harrington Edmund
Ledeboer Mark
Brown Karen K.
Rao Deepak
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
LandOfFree
Inhibitors of c-Jun N-terminal kinases (JNK) and other... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibitors of c-Jun N-terminal kinases (JNK) and other..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitors of c-Jun N-terminal kinases (JNK) and other... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3711472